ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 27,331 shares, a growth of 71.6% from the February 26th total of 15,924 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average trading volume of 13,770 shares, the short-interest ratio is presently 2.0 days.

ImmuCell Stock Performance

ICCC stock traded down $0.01 during trading hours on Friday, hitting $6.52. 9,481 shares of the stock were exchanged, compared to its average volume of 17,627. ImmuCell has a 12 month low of $4.52 and a 12 month high of $7.60. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $59.01 million, a P/E ratio of -59.27 and a beta of 0.27. The company has a 50-day simple moving average of $6.40 and a two-hundred day simple moving average of $6.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Trading of ImmuCell

Hedge funds and other institutional investors have recently bought and sold shares of the business. Steadtrust LLC bought a new stake in ImmuCell in the 3rd quarter valued at about $198,000. Mesirow Financial Investment Management Inc. increased its holdings in shares of ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after buying an additional 2,907 shares in the last quarter. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.